X4 Pharmaceuticals (XFOR) and taiba rare, a healthcare company, announced a strategic exclusive partnership for the distribution and commercialization of XOLREMDI in select Middle East countries, pending regulatory approvals.
XOLREMDI, approved by the U.S. FDA in April 2024, is the first oral treatment for WHIM syndrome, a rare primary immunodeficiency disorder.
WHIM syndrome, characterized by warts, hypogammaglobulinemia, infections, and myelokathexis, affects immune function by impairing neutrophil circulation.
Under the agreement, taiba rare will lead distribution, marketing, and sales in the MENA region (Middle East and North Africa).
Local regulatory filings will follow X4's U.S. FDA submission dossier, and XOLREMDI may be available for compassionate use before approvals.
This collaboration enhances X4's global reach, providing life-changing treatment options for WHIM syndrome patients in the region.
XFOR closed Tuesday's (Feb.18 2025) trading at $0.49 down by 1.97%. In premarket trading Wednesday the stock is up by 4.99% at $0.52.
For comments and feedback: editorial@rttnews.com